Exclusive Summary

• The core patents for loxoprofen sodium patch have expired, eliminating IP barriers and opening a clear window for distribution entry into multiple emerging markets.
• With over 1.7 billion musculoskeletal disease patients globally and a topical NSAID market exceeding USD 5 billion, there is strong and growing demand for effective transdermal analgesics.
• The patch formulation offers a clinically differentiated profile versus oral NSAIDs—lower GI side effects and better patient compliance—making it particularly attractive in aging populations across Asia-Pacific.
• Chinese manufacturers can offer significant cost advantages (typically 20–40% of originator pricing), giving distribution partners strong margin potential in price-sensitive markets.
• The dual-strength format (20mg/40mg) provides flexibility for local registration strategies and market positioning across different therapeutic indications and patient segments.